DORON DINSTEIN

Doron Dinstein is a distinguished Venture Partner, Healthcare at Entrée Capital, a prominent global venture capital firm known for backing transformative technology companies. In his role, Doron leads Entrée Capital's strategic investments within the dynamic and critical healthcare sector. He is instrumental in identifying, evaluating, and nurturing promising startups that are poised to disrupt and advance medical science and patient care.

Doron's investment focus is broad yet deeply specialized, encompassing a wide array of healthcare sub-sectors. He actively seeks out companies developing cutting-edge solutions in biotechnology, pharmaceuticals, medical devices, and digital health. His interest lies in innovative technologies and business models that address significant unmet medical needs, improve healthcare delivery, or enhance patient outcomes. This includes everything from novel drug discovery platforms and advanced therapeutic modalities to smart diagnostics and telehealth solutions. His strategic vision helps Entrée Capital position itself at the forefront of healthcare innovation.

Prior to joining Entrée Capital, Doron Dinstein built an impressive career marked by significant leadership roles within the biopharmaceutical industry. Most notably, he served as the Chief Executive Officer of BioLineRx, a clinical-stage biopharmaceutical company focused on oncology and immunology. During his tenure, he was responsible for advancing several key drug candidates through clinical development and forging strategic partnerships. His extensive experience also includes various senior management positions at major pharmaceutical companies, including Teva Pharmaceutical Industries, where he gained invaluable insights into drug development, commercialization, and global market strategies. This hands-on operational background provides him with a unique perspective, enabling him to deeply understand the challenges and opportunities faced by healthcare entrepreneurs.

Doron holds an MD from Tel Aviv University and an MBA from INSEAD, combining a strong scientific and medical foundation with acute business acumen. This dual expertise allows him to conduct thorough due diligence and provide strategic guidance that goes beyond mere financial investment, offering portfolio companies a true partner in their growth journey. While specific individual investments he has led at Entrée Capital are often part of broader fund activities, his influence is evident in the firm's robust engagement with the healthcare innovation ecosystem. His commitment to fostering groundbreaking healthcare solutions underscores Entrée Capital's dedication to investing in a healthier future.